Author(s):
Abdellatif Bouayyadi, Ahmed Moussaif, Lahcen Bouayyadi, Aissam EL Aliani, Abdelghani Iddar, El Mokhtar Essassi, Aboubaker El Hessni, Mohammed El Mzibri, Abdelhalem Mesfioui
Email(s):
abdellatif_bouayyadi@yahoo.fr
DOI:
10.52711/0974-360X.2026.00012 
Address:
Abdellatif Bouayyadi1, 2*, Ahmed Moussaif1, Lahcen Bouayyadi4, Aissam EL Aliani1, Abdelghani Iddar1, El Mokhtar Essassi3, Aboubaker El Hessni2, Mohammed El Mzibri1, Abdelhalem Mesfioui2
1Division of Life Sciences – National Center for Energy Sciences and Nuclear Techniques – Rabat – Morocco.
2Biology and Health Laboratory – Faculty of Sciences, Ibn Tofail University – Kenitra – Morocco.
3Hassan II Academy of Sciences and Techniques – Rabat – Morocco.
4Biodiversity and Natural Resources Laboratory - Faculty of Sciences, Ibn Tofaïl University – Kenitra – Morocco.
*Corresponding Author
Published In:
Volume - 19,
Issue - 1,
Year - 2026
ABSTRACT:
This work aims to determine the toxicological profile of a new Benzimidazole derivative in the Wistar rat by determining its acute toxicity. The molecule studied; 3-[2-(2-Amino-1H-benzimidazol-1-yl)ethyl]-1,3-oxazolidin-2-one (OXB2) was synthesized in our laboratory and then characterized by several physicochemical techniques. Different doses of OXB2 (500, 600, 700, 800 and 1000 mg/kg) were injected intraperitoneally into five groups of rats in addition to a control group which received only the vehicle solution, and then they were followed daily for 14 days. Food and water consumption, body weight, behavioral changes and mortalities were monitored during this period and the lethal dose 50 (LD50) of this molecule was 854 mg/kg. The molecule studied did not impact food intake or water consumption, body weight or viability of rats administered at a dose of 600 mg/kg. Organ weights were also not affected at this dose and levels of hematological and biochemical values were not affected. The no observed adverse effect level (NOAEL) of OXB2 in Wistar rats confirms this dose. These results suggest that upon further analysis, OXB2 could potentially be tested in preliminary clinical trials.
Cite this article:
Abdellatif Bouayyadi, Ahmed Moussaif, Lahcen Bouayyadi, Aissam EL Aliani, Abdelghani Iddar, El Mokhtar Essassi, Aboubaker El Hessni, Mohammed El Mzibri, Abdelhalem Mesfioui. Acute Toxicity Evaluation of the new Benzimidazole derivative 3-[2-(2-Amino-1H-benzimidazol-1-yl)ethyl]-1,3-oxazolidin-2-one on the Wistar Rat. Research Journal of Pharmacy and Technology. 2026;19(1):76-2. doi: 10.52711/0974-360X.2026.00012
Cite(Electronic):
Abdellatif Bouayyadi, Ahmed Moussaif, Lahcen Bouayyadi, Aissam EL Aliani, Abdelghani Iddar, El Mokhtar Essassi, Aboubaker El Hessni, Mohammed El Mzibri, Abdelhalem Mesfioui. Acute Toxicity Evaluation of the new Benzimidazole derivative 3-[2-(2-Amino-1H-benzimidazol-1-yl)ethyl]-1,3-oxazolidin-2-one on the Wistar Rat. Research Journal of Pharmacy and Technology. 2026;19(1):76-2. doi: 10.52711/0974-360X.2026.00012 Available on: https://rjptonline.org/AbstractView.aspx?PID=2026-19-1-12
REFERENCES:
1. Kale Sachin. C, Upadhayay Ashutosh, Kale M. K. Synthesis, Medicinal Applications and QSAR Study of Benzimidazole, Thiophene, Piperazine derivatives for Antimycobacterial, Antibacterial, Antifungal Activities. Research J. Pharm. and Tech. 2018; 11(12): 5385-5393. doi: 10.5958/0974-360X.2018.00983.6
2. Michele Tonelli, Giuseppe Paglietti, Vito Boido, Fabio Sparatore, Fabio Marongiu, Esther Marongiu, Paolo La Colla, Roberta Loddo. Antiviral activity of benzimidazole derivatives. I. Antiviral activity of 1-substituted-2-[(benzotriazol-1/2- yl)methyl]benzimidazoles. Chem Biodivers. 2008; 5(11): 2386-401.doi.org/10.1002/cbdv.200890203
3. Nandini R Pai, Deepnandan S Dubhashi. Pharmacological Evaluation of Substituted Benzeneacetic Acid Ester Derivatives for Their Sedative, Antibacterial and Antifungal Potential. Research J. Pharm. and Tech. 2010; 3(2): 570-577.
4. Chaitanya Prasad Meher, Abinash Kumar Sahu, Srimanta Kumar Dash, Ranjan Kumar Sahoo, Subodha Chandra Sahu, Dillip Kumar Gupta. Designing and Synthesis of some Novel 2-Substituted Benzimidazole Derivatives and their Evaluation for Antimicrobial and Anthelmintic Activity. Asian J. Research Chem. 2019; 12(2): 58-62. doi: 10.5958/0974-4150.2019.00013.0
5. Sudheer K Dokuparthi, J. Baloji Naik K. Sunil Kumar, A. Saidulu. Synthesis, Characterization and Biological Evaluation of Benzimidazole Derivatives as Potential Anxiolytics. Research J. Pharm. and Tech. 2018; 11(1): 221-226. doi: 10.5958/0974-360X.2018.00041.0
6. Deepak Kardile, Mrunal Shirsat. In vitro Antimicrobial and Antitubercular screening of newly synthesized Mercaptobenzimidazole –club bed chalcone derivatives. Research J. Pharm. and Tech. 2021; 14(1): 450-454. doi: 10.5958/0974-360X.2021.00082.2
7. D. S. Bele, I. Singhvi. Synthesis and Analgesic Activity of Some Mannich Bases of 6-Substituted-2-Aminobenzothiazole. Research J. Pharm. and Tech. 2008; 1(1): 22-24.
8. Ravi N Tiwari, KG Bothara, Gurmeet Singh Chhabra, Sarang Kulkarni. Evaluation of Anticonvulsant Activity of Novel Substituted 2-Mercaptobenzimidazole Derivatives. Research J. Pharm. and Tech. 2010; 3(2): 466-467.
9. Viral Patel. Design, Development, Evaluation and Optimization of Antiulcer Delayed Release Tablets. Research J. Pharm. and Tech. 2013; 6(6): 669-684.
10. Deepak Kardile, Mrunal Shirsat. Synthesis and Evaluation of Antimicrobial, Antitubercular and Anticancer activities of Dihydrobenzimidazolethiopyrano oxazinone derivatives. Research J. Pharm. and Tech. 2021; 14(3): 1453-1458. doi: 10.5958/0974-360X.2021.00259.6
11. Kanimozhi.P, Karthikeyan. J. Modulation of Antioxidant Potential in Liver of Albino rats by seeds of Nelumbo nuciferaGaertn. in 1,4 Dichlorobenzene induced hepatotoxicity. Research J. Pharm. and Tech. 2012; 5(4): 538-540.
12. Sanjeev Sharma, P.D. Gokulan, P.S. Jadon, Sanjay Singh, S.S. Shukla. Synthesis and Biological Evaluation of Some New BenzimidazoleDerivatives For theirAnticonvulsant and Anti-inflammatoryactivity. Research J. Pharm. and Tech. 2011; 4(8): 1311-1319.
13. Bouayyadi A, el al. Molecular docking analysis of α2-containing GABAA receptors with benzimidazoles derivatives. Bioinformation. 2020 Aug 31; 16(8): 611-619. doi: 10.6026/97320630016611. PMID: 33214749; PMCID: PMC7649024.
14. Bouayyadi A, el al. Molecular docking of an antianxiety drug molecule "3-[2-(1H-Benzimidazol-2-ylsulfan-yl) eth-yl]-1,3-oxazolidin-2-one". Int. J. Computational Biology and Drug Design. July 29, 2022, 15(1), pp. 30–42. doi.org/10.1504/IJCBDD.2022.124757.
15. El Harti Jaouad, Adouani Badr, Benmoussa Adnane, Ansar M’hammed, Taoufik Jamal. Benzimidazoles and Pharmacological Activities: A Review. Research J. Pharm. and Tech. 2014; 7(4): 481-488.
16. Yogendra Nayak, Jayashree B.S., Unnikrishnan M.K. Benzopyran-4-one is an Ideal Pharmacophore for Lead Optimization in Antidiabetic Drug Discovery. Research J. Pharm. and Tech. 2012; 5(8): 1025-1033.
17. Gurvinder, S et al. Int. Res. J. Pharm. 4 (2013): 82-87.
18. Bouayyadi A, el al. Acute Toxicity Evaluation of a new Benzimidazole derivative on the wistar rat. Research Journal of Pharmacy and Technology. 2022; 15(6): 2427–2432. doi.org/10.52711/0974-360X.2022.00404
19. Bouayyadi A et al. Synthesis and characterization of novel Benzimidazole derivatives. World Journal of Pharmaceutical Research. 2016 5(7):61
20. Bouayyadi A, et al. 3-[2-(2-Amino-1H-benzo [d] imidazol-1-yl) ethyl]-1, 3-oxazolidin-2-one IUCr Data. Dec 2016; 1: 12 doi.org/10.1107/S2414314616018952
21. Viala A and Botta A. (2005). Toxicologie, 2 eme edition. Paris: Tec α Doc Lavoisier, 25-46.
22. Organisation for Economic Cooperation and Development (OECD), Harmonized Integrated Hazard Classification System for Human Health and Environmental Effects of Chemical Substances, Part 2, Paris 2001, pp. 20–24.
23. Descat Fleur., Hématologie du rat: Hémogramme et myogramme, Thèse, Université de Toulouse, 2002. P.91-93.
24. Lazare, T et al. Alcoolisation chronique des rats (Rattusnorvegicus) de souche Wistar à une eau-de-vie traditionnelle produit en Côte d’Ivoire (Koutoukou). Journal of Applied Biosciences. 2011; 41: 2772-2779.
25. Bouayyadi A, et al. 3-[2-(2-amino-1h-benzimidazol-1-yl) éth¬yl]-1,3-oxazolidin-2-one comme composé présentant une activité sélective vis-à-vis la sous unité alpha 2 du récepteur GABAA pour le traitement de l’anxiété et la dépression. OMPIC – May 2024 - Patent n° [MA54635]. http://patent.ompic.ma/search
26. Archives Internationales de Pharmacodynamie et de Thérapie, vol. 95, p. 123, 1953.
27. Xiong H. and Pamer E.G. Monocytes and infection: Modulator, messenger and effector, Immunobiology. 2015; 220(2): 210–214.
28. Willhite, C.C and Katz, P.I. (Toxicology Updates: DimethylSulfoxide. Journal of Applied Toxicology. 1984; 4(3): 155-160
29. Sirwal I.A, et al. (2004). Estimation of glomerular filteration rate (GFR). JK Science. 2004; 6(3): 121-3.